Thus, our study not only identifies EZH2T367p as a biomarker for the prediction of colon cancer but also provides the evidence that targeting DCAF1 kinase activity toward EZH2 is a promising strategy for tackling colon cancer development. Here, EZH2 is linked to malignant colon neoplasm.